vs 6,526 other HR bills in the 114th — cohort avg 56d
Summary
Pharmacy and Medically Underserved Areas Enhancement Act Amends title XVIII (Medicare) of the Social Security Act to cover pharmacist services.
Lobbying filings that explicitly cite this bill (50)
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Cited source text, amounts, lobbyists, and targets
S. 483 (114th Congress) legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, provide for coverage under Medicare program of pharmacist services. Medication Therapy Management. H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; FDA implementation of Section 503B of the Food, Drug, and Cosmetic Act; House & Senate Agriculture, FDA & Related Agency Appropriations bills; H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. Prescription Drug Importation including S. 771 and H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S.469, the Affordable and Safe Prescription Drug Importation Act. E-Prescribing bills including H.R. 3528 and S. 2460, the Every Prescription Conveyed Securely (EPCS) Act. H.R. 5958, Phair Pricing Act of 2018. HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018. H.R. 6, SUPPORT for Patients and Communities Act.
Client expense: $450,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Cited source text, amounts, lobbyists, and targets
S. 483 (114th Congress) legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, provide for coverage under Medicare program of pharmacist services. Medication Therapy Management. H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; FDA implementation of Section 503B of the Food, Drug, and Cosmetic Act; House & Senate Agriculture, FDA & Related Agency Appropriations bills; H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. Prescription Drug Importation including S. 771 and H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S.469, the Affordable and Safe Prescription Drug Importation Act. E-Prescribing bills including H.R. 3528 and S. 2460, the Every Prescription Conveyed Securely (EPCS) Act. H.R. 5958, Phair Pricing Act of 2018. HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018.
Client expense: $470,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
S. 483 (114th Congress) legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, provide for coverage under Medicare program of pharmacist services. Medication Therapy Management. H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; FDA implementation of Section 503B of the Food, Drug, and Cosmetic Act; House & Senate Agriculture, FDA & Related Agency Appropriations bills; H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. Prescription Drug Importation including S. 771 and H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S.469, the Affordable and Safe Prescription Drug Importation Act. E-Prescribing bills including H.R. 3528 and S. 2460, the Every Prescription Conveyed Securely (EPCS) Act. H.R. 5958, Phair Pricing Act of 2018. HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Client expense: $460,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
S. 483 (114th Congress) legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, provide for coverage under Medicare program of pharmacist services. Medication Therapy Management. H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; FDA implementation of Section 503B of the Food, Drug, and Cosmetic Act; House & Senate Agriculture, FDA & Related Agency Appropriations bills; H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. Prescription Drug Importation including S. 771 and H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S.469, the Affordable and Safe Prescription Drug Importation Act. E-Prescribing bills including H.R. 3528 and S. 2460, the Every Prescription Conveyed Securely (EPCS) Act.
Client expense: $660,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
S. 483 (114th Congress) legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 10385 and S. 413, legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; FDA implementation of Section 503B of the Food, Drug, and Cosmetic Act; House & Senate Agriculture, FDA & Related Agency Appropriations bills; H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. Prescription Drug Importation including S. 771 and H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S.469, the Affordable and Safe Prescription Drug Importation Act S. 413 and H.R. 1038 Medicare Part D and Pharmacy Reimbursement.
Client expense: $580,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, White House Office
Cited source text, amounts, lobbyists, and targets
Enactment of S. 483 (114th Congress) legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 10385 and S. 413, legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; FDA implementation of Section 503B of the Food, Drug, and Cosmetic Act; House & Senate Agriculture, FDA & Related Agency Appropriations bills; H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. Prescription Drug Importation including S. 771 and H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S.469, the Affordable and Safe Prescription Drug Importation Act S. 413 and H.R. 1038 Medicare Part D and Pharmacy Reimbursement.
Client expense: $330,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act. S. 413 and H.R. 1038 Medicare Part D and Pharmacy Reimbursement.
Client expense: $310,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act.
Client expense: $350,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
S. 776, Medication Therapy Management Empowerment Act of 2015.
H.R. 592/S. 314, Pharmacy and Medically Underserved Areas Enhancement Act.
H.R. 793/S. 1190, Ensuring Seniors Access to Local Pharmacies Act of 2015.
H.R. 244, MAC Transparency Act.
H.R. 5951/S. 3308, Improving Transparency and Accuracy in Medicare Part D Spending Act.
Client expense: $210,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Cited source text, amounts, lobbyists, and targets
Reimbursement of Pharmacist Services - HR592/S314
Transitions of Care
Track and Trace/Supply Chain
Health Information Technology
Immunizations
Compounding
Tele-Medicine
Quality Rating
AMP FULs/MAC Pricing
Biosimiliars/Biologic Products (S 2700)
Drug Importation
Generics Labeling
Pharmacy Benefit Managers
Preferred Pharmacy Network (HR793)
Electronic Labeling
21st Century Cures/Innovation Bills (HR6, HR34)
Drug Disposal/Management
Drug Prices
Direct and Indirect Remuneration Fees (HR 5951, S3308)
Lab Developed Tests
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Cited source text, amounts, lobbyists, and targets
Pharmacy and Medically Underserved Areas Enhancement Act (S. 314 and HR 592), to amend Title IIX of the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved areas.
Client expense: Not reported · Firm income: $60,000
Cited source text, amounts, lobbyists, and targets
HR 6, 21st Century Cures Act;
HR 592/S 314, Pharmacy and Medically Underserved Areas Enhancement Act;
S 524, Comprehensive Addiction and Recovery Act of 2016; provisions related to pharmacy and consultant pharmacy
Client expense: Not reported · Firm income: $40,000
Cited source text, amounts, lobbyists, and targets
Excellence in Mental Health Act (S.264); Medicaid and Medicare payment for Health Centers; Medicare Chronic Care Coordination; Medicaid quality reporting; Childrens Health Insurance Program (CHIP); Pharmacy Provider Status legislation(H.R.592/S.314); The Rural ACO Improvement Act of 2015(S.1456, S.2259 & S.2261); Telehealth legislation; Connect for Health Act (H.R.4442/S.2484); Incentivizing Medicaid Expansion Act(H.R.4588); ECHO Act (H.R.5395/S.2873); Rural ACO Provider Equity Act (H.R.5667); Rural Access to Hospice Act(H.R.5799).
Client expense: $290,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
Cited source text, amounts, lobbyists, and targets
Issues related to prescription drug abuse, preferred pharmacy networks, medication adherence, and drug pricing.
HR 592 - Pharmacy and Medically Underserved Areas Enhancement Act
S 314 - Pharmacy and Medically Underserved Areas Enhancement Act
HR 244 - MAC Transparency Act
S.3056-the Creating and Restoring Equal Access to Equivalent Samples Act (CREATES)
Client expense: $2,080,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA)
Cited source text, amounts, lobbyists, and targets
S. 776, Medication Therapy Management Empowerment Act of 2015.
H.R. 592/S. 314, Pharmacy and Medically Underserved Areas Enhancement Act.
H.R. 793/S. 1190, Ensuring Seniors Access to Local Pharmacies Act of 2015.
H.R. 244, MAC Transparency Act.
H.R. 5951/S. 3308, Improving Transparency and Accuracy in Medicare Part D Spending Act.
Client expense: $180,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cited source text, amounts, lobbyists, and targets
S.J.Res.38 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule relating to the extent to which employers may use incentives to encourage employees to participate in wellness programs that ask the employees to respond to disability-related inquiries or undergo medical examinations.
Oversight/Implementation/Amendments to Patient Protection and Affordable Care Act (P.L. 111-148) - Sections 1201; 1301; 1302; 1303; 1311; 1341; 1401; 1411; 1412; 1414; 1502; 1511; 1512; 1513; 1514; 4205; 9001; 9010
H.R. 30 - To amend the Internal Revenue Code of 1986 to repeal the 30-hour threshold for classification as a full-time employee for purposes of the employer mandate in the Patient Protection and Affordable Care Act and replace it with 40 hours.
S. 30 - To amend the Internal Revenue Code of 1986 to modify the definition of full-time employee for purposes of the employer mandate in the Patient Protection and Affordable Care Act.
H.R. 1189/S. 620 - To clarify rules relating to nondiscriminatory employer wellness programs as such programs relate to premium discounts, rebates, or modifications to otherwise applicable cost sharing under group health plans.
H.R 1270/S. 254 - To amend the Internal Revenue Code of 1986 to repeal the amendments made by the Patient Protection and Affordable Care Act which disqualify expenses for over-the-counter drugs under health savings accounts and health flexible spending arrangements.
H.R. 2050 - To amend the Internal Revenue Code of 1986 to repeal the excise tax on high cost employer-sponsored health coverage
H.R. 879 - To repeal the Cadillac Tax on middle class Americans health plans.
H.R. 1886 - To amend section 1341 of the Patient Protection and Affordable Care Act to repeal the funding mechanism for the transitional reinsurance program in the individual market, and for other purposes.
H.R. 2712 - To streamline the employer reporting process and strengthen the eligibility verification process for the health care premium tax credit and cost-sharing subsidy, and for other purposes.
H.R. 2017 - To amend the Federal Food, Drug, and Cosmetic Act to improve and clarify certain disclosure requirements for restaurants and similar retail food establishments, and to amend the authority to bring proceedings under section 403A.
H.R. 928/S. 183 - To repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act.
H.R. 3112 - BE OPEN Act
S. 1996 - Commonsense Reporting Act of 2015
S. 2045 - Middle Class Health Benefits Tax Repeal Act of 2015
S. 2075 - American Worker Health Care Tax Relief Act of 2015
H.R. 592 / S. 314 - Pharmacy and Medically Underserved Areas Enhancement Act
H.R.3762 - Restoring Americans' Healthcare Freedom Reconciliation Act of 2015
S.1946 - Tax Relief Extension Act of 2015
S.2045 - Middle Class Health Benefits Tax Repeal Act of 2015
Client expense: $100,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
H.R.3250/S. 2994 - DXM Abuse Prevention Act of 2015
H.R. 1270 / S. 620 - Restore Access to Medication Act
H.R. 592 / S. 314 - Pharmacy and Medically Underserved Areas Enhancement Act
H.R.3762 - Restoring Americans' Healthcare Freedom Reconciliation Act of 2015
H.R. 793/S. 1190 - the Ensuring Seniors Access to Local Pharmacies Act
Health Savings Act of 2016 - H.R.4469/S.2499
H.R. 5951/S. 3308 - Improving Transparency and Accuracy in Medicare Part D Spending Act
Client expense: $100,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Institutes of Health (NIH), SENATE, Veterans Affairs, Dept of (VA), Vice President of the U.S.
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Cited source text, amounts, lobbyists, and targets
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
Client expense: $610,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.
Client expense: $1,000,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
Issues related to CARA Act; Issues related to Pharmacy Regulation; Issues related to HR 592, Pharmacy and Medically Underserved Areas Enhancement Act; Issues related to HR 793/ S. 1190, Ensuring Seniors Access to Local Pharmacies Act of 2015; Issues related to 21st Century Cures; Issues related to HR 244, MAC Transparency Act.
Client expense: Not reported · Firm income: $90,000
Cited source text, amounts, lobbyists, and targets
Issues related to CARA Act; Issues related to Pharmacy Regulation; Issues related to HR 592, Pharmacy and Medically Underserved Areas Enhancement Act; Issues related to HR 793/ S. 1190, Ensuring Seniors Access to Local Pharmacies Act of 2015; Issues related to 21st Century Cures; Issues related to HR 244, MAC Transparency Act.
Client expense: Not reported · Firm income: $90,000
Cited source text, amounts, lobbyists, and targets
H.R. 546/S. 298, the ACE Kids Act of 2015, all provisions. H.R. 3716, Ensuring Access to Quality Medicaid Providers Act, all provisions. H.R. 592/S. 314, the Pharmacy and Medically Underserved Areas Enhancement Act, all provisions. General issues related to infant mortality, public health, and research.
Client expense: $120,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
H.R. 3762, Restoring Americans Healthcare Freedom Reconciliation Act
H.R. 592/S. 314, Pharmacy and Medically Underserved Areas Enhancement Act
H.R. 954, CO-OP Consumer Protection Act of 2016
H.R. 1190/S. 141, The Protecting Seniors Access to Medicare Act of 2015
H.R. 1192, National Clinical Care Commission Act
H.R. 1270, Restoring Access to Medication and Improving Health Savings Act
H.R. 1427, Medicare CGM Access Act
H.R. 1686/S. 3082, Preventing Diabetes in Medicare Act
H.R. 1707, Access to Frontline Health Care Act of 2015
H.R. 1726, Access to Quality Diabetes Education Act
H.R. 1807, Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2015
H.R. 2102, Medicare Diabetes Prevention Act
H.R. 2124/S. 1148, Resident Physician Shortage Act
H.R. 2603/S. 1475, Saving Lives, Saving Costs Act
H.R. 2646, Helping Families in Mental Crisis Act
H.R. 2713/S. 3245, Title VIII Nursing Workforce Reauthorization Act of 2016
H.R. 3081/S. 1778, Telemedicine for Medicare Act
H.R. 3119/S. 2748, Palliative Care and Hospice Education and Training Act
H.R. 3660/S. 3126,Preventive Health Savings Act
H.R. 3952/S. 2248, Congenital Heart Future Reauthorization Act of 2015
H.R. 4212/S. 704, Community Based Independence for Seniors Act of 2015
H.R. 4442/S. 2484, CONNECT for Health Act
H.R. 4732/S. 2671, Advancing Medical Resident Training in Community Hospitals Act
H.R. 4774, Training Tomorrows Doctors Today Act
H.R. 4909/S. 2943, National Defense Authorization Act
H.R. 5273, Helping Hospitals Improve Patient Care Act
H.R. 5414, FDA Cross-Center Collaboration Act
H.R. 5447/S. 3060, The Small Business Health Care Relief Act
H.R. 5652,Access to Better Care Act
H.R. 5681/S. 3137, Alzheimers Beneficiary and Caregiver Support Act
H.R. 5713, Sustaining Healthcare Integrity and Fair Treatment Act of 2016
H.R.5926 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017
H.R. 6043/S. 3335, The Fair Accountability and Innovative Research Drug Pricing Act of 2016
H.R. 6109/S. 3371, Medicare Affordability and Enrollment Act
S. 524, Comprehensive Addiction and Recovery Act
S. 586, National Diabetes Clinical Care Commission Act
S. 603, Jobs and Premium Protection Act
S. 776,Medication Therapy Management Empowerment Act
S. 1077,Advancing Breakthrough Medical Devices for Patients Act
S. 1101,Medical Electronic Data Technology Enhancement for Consumers Health (MEDTECH) Act
S. 1622,FDA Device Accountability Act
S. 2511,Improving Health Information Technology Act
S. 2680,Mental Health Reform Act of 2016
S. 2864,Reducing Existing Costs Associated with Pharmaceuticals for Seniors Act of 2016
S. 3326,State Flexibility to Provide Affordable Health Options Act
S. 3504, Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2016
Pub. L. 111-5, The American Recovery and Reinvestment Act of 2009 (Health Information Technology for Economic and Clinical Health Act (HITECH)
Pub. L. 111-148, Patient Protection and Affordable Care Act (PPACA)
Pub. L. 114-10, Medicare Access and CHIP Reauthorization Act (MACRA)
Pub. L. 114-255,21st Century Cures
Pub. L. 114-270, Expanding Capacity for Health Outcomes Act (ECHO)
Pub. L. 114-328, National Defense Authorization Act for Fiscal Year 2017
Client expense: $150,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cited source text, amounts, lobbyists, and targets
S. 314 - Pharmacy and Medically Underserved Areas Enhancement Act
H.R. 592 - Pharmacy and Medically Underserved Areas Enhancement Act
H.R. 1270 - Restoring Access to Medication Act of 2015
S. 709 - Restoring Access to Medication Act of 2015
S.776 - Medication Therapy Management Empowerment Act of 2015
H.R. 793 - Ensuring Seniors Access to Pharmacies Act of 2015
H.R. 1021, the Protecting the Integrity of Medicare Act (PIMA) of 2015
H.R.2 - Medicare Access and CHIP Reauthorization Act of 2015
H.R.6 - 21st Century Cures Act
S.1190 - Ensuring Seniors Access to Local Pharmacies Act of 2015
S. 1913 - Stopping Medication Abuse and Protecting Seniors Act of 2015
H.R.4878 - Better Care, Lower Cost Act
S. 3094 - Price Relief, Innovation, and Competition for Essential Drugs Act
HR 5573 - Price Relief, Innovation and Competition for Essential Drugs Act
H. R. 4641 -To provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
HR 5210-Patient Access to Durable Medical Equipment Act
S 2736-Patient Access to Durable Medical Equipment Act of 2016
H.R. 1192 - National Diabetes Clinical Care Commission Act
S. 3056 - Creating and Restoring Equal Access to Equivalent Samples Act
H.R. 5951- Improving Transparency and Accuracy in Medicare Part B Spending
Client expense: $380,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Cited source text, amounts, lobbyists, and targets
Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including implementation of the Drug Quality and Security Act (P.L.113-54) and P.L.112-144; support medical device pricing transparency and prohibition on medical device price "gag clauses"; preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases and support draft reform legislation; pharmaceutical labeling of generic drugs (FDA-2013-N-0500); legislation to create a comprehensive Medicare home infusion benefit (H.R.605/S.275) - support; support reforming the durable medical equipment competitive bidding program; supporting "any willing pharmacy" legislation; promoting access to biosimilars (labeling/interchangeability); 21st Century Cures Act (H.R.6) - general support for overall bill, support final pharmacy lock-in policy, oppose PPSA weakening of existing requirements, oppose Section 4004 treatment of infusion drugs furnished through durable medical equipment, oppose use of savings from home infusion payment reform for purposes other than creating a Medicare home infusion benefit; Ensuring Seniors Access to Local Pharmacies Act (H.R.793/S.1190) - support; Pharmacy and Medically Underserved Areas Enhancement Act (H.R.592/S.314) - support; MAC Transparency Act (H.R.244) - support; Medication Therapy Management Empowerment Act (S.776) - support; Strengthening Medicare Advantage Through Innovation and Transparency for Seniors - oppose; FDA-2014-D-1524-0002 - comments, Administration and Capitol Hill meetings on draft guidance on repackaging of certain human drug products by pharmacies and outsourcing facilities; FDA-2014-N-1459 - comments and Capitol Hill meetings on draft MOU addressing certain distributions of compounded human drug products between states and the FDA; proposed changes to the 340B prescription drug program - oppose; 21st Century Cures Act (H.R.6, now P.L.114-255) - support, but with serious concerns about the misalignment of implementation dates for two home infusion provisions - oppose implementation of Section 5004 (a) without aligning the start date of the new Medicare home infusion service benefit in Section 5012; proposed amendments to 340b program (not ultimately included in H.R.6) - oppose; provide comments on proposed 340b omnibus guidance (RIN 0906 AB08); Stopping Medication Abuse and Protecting Seniors Act of 2015 (S.1913)- support (with some concerns about pharmacy lock-in policy); submitted comments on Management Standards for Hazardous Waste Pharmaceuticals (EPA-HQ-RCRA-2007-0932); meeting with DEA on Controlled Substances Act (21 USC 802); proposed changes to regulation of Laboratory Developed Tests (FDA-2011-D-0360-Draft Guidance for Industry, Food and Drug Administration Staff and Clinical Laboratories: Framework for Regulatory Oversight of Laboratory Developed Tests) - oppose; Comprehensive Addiction and Recovery Act of 2016 ((S.524), monitoring for pharmacy lock-in policy, which includes exemption for LTC) - support; Increasing Competition in Pharmaceuticals Act (S.2615/H.R.4784) - support; CREATES Act addressing REMS abuses (S.3056) - support; submitted comments in response to HRSA proposed rule establishing an Administrative Dispute Resolution (ADR) Process for the 340B Drug Purchasing Program (81 Fed. Reg. 53,381).
Client expense: $400,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
Cited source text, amounts, lobbyists, and targets
Graduate Medical Education (GME) issues (including Resident Physician Shortage Reduction Act (H.R.2124/S.1148) - support); provided comments to Congress in response to Energy and Commerce Committee request for input on GME; amendments to the Medicare hospital re-admissions penalty program methodology (providing SES adjustments, fixing the formula flaw), H.R.1343/S.688 - support; proposals to amend the 2 midnight policy - support; hospital issues included in President Obama's FY 16 budget - oppose; hospital issues included in H.R.2, the Medicare Access and CHIP Re-authorization Act of 2015 - support; legislation to create a comprehensive Medicare home infusion benefit (H.R.605/S.275) - support; Strengthening Medicare Advantage through Innovation and Transparency for Seniors (H.R.2570) - oppose; Medicare Inpatient Prospective Payment System FY 2016 proposed rule (CMS 1632-P) - detailed comment letter; legislation to improve the recovery audit contractor program (H.R.2156); Audit and Appeal Fairness, Integrity and Reforms in Medicare Act (AFIRM) - provided comments to the Senate Finance Committee; Ensuring Seniors Access to Local Pharmacies Act of 2015 (H.R.793/S.1190) - support; Pharmacy and Medically Underserved Areas Enhancement Act (H.R.592/S.314) - support; MAC Transparency Act (H.R.244) - support; Medication Therapy Management Act (S.776) - support; CMS-4159-F2 - comments on daily dispensing fees; Medicare Independence at Home Medical Practice Demonstration Improvement Act of 2015 (P.L.114-39) - support; provided comments on the proposed Medicare outpatient prospective payment system rule (CMS-1633-P); Medicare IME Pool Act of 2015 (H.R.3292) - oppose; Strengthening DSH and Medicare through Subsidy Recapture and Payment Reform Act (H.R.3288) - oppose; Medicare Crosswalk Hospital Code Development Act (H.R. 3291) - oppose; sign-on letter to CMS urging it to reconsider negative update for CY 2016 (CMS-1633-P) - support; proposed Medicare and Medicaid cuts as offsets to pay for budget increases, raising the debt ceiling, etc. - oppose; site neutral hospital outpatient cuts and other hospital related provisions included in the Bipartisan Budget Act of 2015 (H.R. 1314) - oppose; legislative proposals (H.R. 5273)and Congressional letters to amend the Bipartisan Budget Acts site neutral hospital outpatient payment cut to grandfather sites under development as well as other legislative changes (support) - advocated for their inclusion in the Consolidated Appropriations Act of 2016 (Omnibus legislation/Senate amendment to H.R. 2029); provided comments to Congress regarding provisions in the Mental Health Reform Act of 2015 (S. 1945), that would reform how health care information for substance abuse patients is shared; met with HHS officials on Medicare and Medicaid issues of importance to the Commonwealth of Puerto Rico and Puerto Rican health care providers; submitted comments on Medicare and Medicaid Programs: Reform of Requirements for Long-Term Care Facilities (CMS-3260-P); Stopping Medication Abuse and Protecting Seniors Act of 2015 (S.1913) - support (with some concerns about pharmacy lock-in policy); hospital issues included in House FY 17 budget - oppose; hosptial issues included in President Obama's FY 17 budget proposal - oppose; provided comments in response to Energy and Commerce Committee request for input on hospital site-neutral issues; Medicaid provisions included in the Common Sense Savings Act of 2016 (H.R.4725) - oppose; provided comments to CMS and Congress regarding the Hospital Compare Star Ratings for hospitals - support for delay and fixing measures; The Fair Medicare Hospital Payments Act of 2016 (H.R. 4428) - oppose; provided comments to CMS on hospital site-neutral proposals - argued for flexibility in the anticipated OPPS proposed rule; provided comments to CMS on the FY 17 IPPS proposed rule (CMS-1655-P) with a focus on opposition to the proposed Medicare DSH policy and provided input to Capitol Hill and the Administration;submitted comments on Medicaid Program,Covered Outpatient Drugs (CMS-2345-FC); asked Congressional members to urge CMS to finalize its 2014 proposed guidance to Part D drug plans and PBMs regarding consistent reporting of Direct and Indirect Remuneration (DIR); Improving Transparency & Accuracy in Medicare Part D Spending (S.3308/H.R.5957) - support; testified at House Ways and Means Health Subcommittee hearing entitled "Incentivizing Quality Outcomes in Medicare Part A" in support of streamlining hospital measures and reporting; provided comments regarding the Medicare OPPS CY2017 proposed rule (81 FR 45603), in particular in opposition to implementation of site-neutral proposals; provided comments on Merit Based Incentive Payment System (MIPS)and Alternative Payment Models (APMs) under MACRA 2015 (81 FR 28161); discussions with CMS regarding priority categories for redistribution of Medicare-funded residency slots; discussions with CMS to encourage consistency in hospital surveys; submitted comments on the Part B Drug Payment Model proposed rule (CMS-1670-P) - serious concerns; submitted comments on the SNF PPS proposed rule (CMS-1645-P) - serious concerns; Texas proposed Medicaid State Plan Amendment (15-005) in response to the CMS Covered Outpatient Drug Rule (CMS-2345-FC) - concerns; submitted comments to CMS about its proposal to expand testing of mandatory, risk-based bundled payments for acute episodes of care - oppose; 21st Century Cures Act (H.R. 34, now P.L.114-255) provisions that apply to site neutral, readmissions, and other hospital reimbursement issue - support.
Client expense: $400,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
Cited source text, amounts, lobbyists, and targets
S. 776 - Medication Therapy Empowerment Act of 2015;
H.R. 1021 - Protecting the Management Integrity of Medicare Act of 2015;
H.R. 1270 - Restoring Access to Medication Act of 2015;
S. 709- Restoring Access to Medication Act of 2015;
H.R. 2- Medicare Access and Chip Reauthorization Act of 2015;
H.R. 793 - Ensuring Seniors Access to Local Pharmacies Act of 2015;
S. 1190 -Ensuring Seniors Access to Local Pharmacies Act of 2015;
S. 314 - Pharmacy and Medically Underserved Areas Enhancement Act;
H.R. 592 - Pharmacy and Medically Underserved Areas Enhancement Act;
H.R. 5951/S. 3308 - Improving Transparency and Accuracy in Medicare Part D Spending Act
Client expense: $245,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), Office of Personnel Management (OPM), SENATE
Cited source text, amounts, lobbyists, and targets
ACA Implementation, PL 111-148, including: Food and Drug Administration regulations relating to menu labeling. H.R. 1270/S. 709, Restoring Access to Medication Act, all provisions. H.R. 1886, Repeal the funding mechanism for the transitional reinsurance program of ACA, all provisions. H.R. 592/S. 314, Pharmacy and Medically Underserved Areas Enhancement Act, all provisions. H.R. 2712, the Commonsense Reporting and Verification Act of 2015, all provisions. S. 1996, the Commonsense Reporting Act of 2015, all provisions.
Client expense: $220,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
H.R. 592/S. 314, Pharmacy and Medically Underserved Areas Enhancement Act, all provisions. H.R. 4909, FY 2017 National Defense Authorization Act, provisions related to TRICARE and pharmacy access. H.R. 953/S. 524, Comprehensive Addition and Recovery Act, provisions related to state prescription drug monitoring programs. H.R. 793/S. 1190, Ensuring Seniors Access to Local Pharmacies Act of 2015, all provisions. H.R. 3250, DXM Abuse Prevention Act, provisions related to retail pharmacy.
Client expense: $220,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, MIPSA/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about recent FDA guidance on compounding and increasing prescription drug pricing.Communication with CMS regarding Part B payment demonstration.
Client expense: $230,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
H.R. 592/S.314 Pharmacy and Medically Underserved Areas Enhancement Act. IPC is supportive of pharmacists being recognized as providers under Medicare Part B for these areas.
H.R. 793 Ensuring Seniors Access to Local Pharmacies Act. IPC is support of local pharmacies being able to participate in Medicare Part D in these underserved areas.
S.524 Comprehensive Addiction and Recovery Act of 2016. IPC was against law as written.
Actual Acquisition Cost (AAC) adoption with state Medicaid programs.
Client expense: $30,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
S. 776, Medication Therapy Management Empowerment Act of 2015.
H.R. 592/S. 314, Pharmacy and Medically Underserved Areas Enhancement Act.
H.R. 793/S. 1190, Ensuring Seniors Access to Local Pharmacies Act of 2015.
H.R. 244, MAC Transparency Act.
H.R. 5951/S. 3308, Improving Transparency and Accuracy in Medicare Part D Spending Act.
Client expense: $190,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cited source text, amounts, lobbyists, and targets
Issues related to prescription drug abuse, preferred pharmacy networks, medication adherence, and drug pricing. Issues related to FDA repackaging and drug disposal.
HR 1600 :A bill to amend title XXVII of the Public Health Service Act to limit co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier to the dollar amount (or its equivalent) of such requirements applicable to prescription drugs in a non-preferred brand drug tier, and for other purposes.
HR 592 - Pharmacy and Medically Underserved Areas Enhancement Act
S 314 - Pharmacy and Medically Underserved Areas Enhancement Act
HR 244 - MAC Transparency Act
S. 524, HR 953-Comprehensive Addiction and Recovery Act
HR 4909-National Defense Authorization Act
S 2943--National Defense Authorization Act
S.3056-the Creating and Restoring Equal Access to Equivalent Samples Act (CREATES)
Client expense: $1,320,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
S.J.Res.38 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule relating to the extent to which employers may use incentives to encourage employees to participate in wellness programs that ask the employees to respond to disability-related inquiries or undergo medical examinations.
Oversight/Implementation/Amendments to Patient Protection and Affordable Care Act (P.L. 111-148) - Sections 1201; 1301; 1302; 1303; 1311; 1341; 1401; 1411; 1412; 1414; 1502; 1511; 1512; 1513; 1514; 4205; 9001; 9010
H.R. 30 - To amend the Internal Revenue Code of 1986 to repeal the 30-hour threshold for classification as a full-time employee for purposes of the employer mandate in the Patient Protection and Affordable Care Act and replace it with 40 hours.
S. 30 - To amend the Internal Revenue Code of 1986 to modify the definition of full-time employee for purposes of the employer mandate in the Patient Protection and Affordable Care Act.
H.R. 1189/S. 620 - To clarify rules relating to nondiscriminatory employer wellness programs as such programs relate to premium discounts, rebates, or modifications to otherwise applicable cost sharing under group health plans.
H.R 1270/S. 254 - To amend the Internal Revenue Code of 1986 to repeal the amendments made by the Patient Protection and Affordable Care Act which disqualify expenses for over-the-counter drugs under health savings accounts and health flexible spending arrangements.
H.R. 2050 - To amend the Internal Revenue Code of 1986 to repeal the excise tax on high cost employer-sponsored health coverage
H.R. 879 - To repeal the Cadillac Tax on middle class Americans health plans.
H.R. 1886 - To amend section 1341 of the Patient Protection and Affordable Care Act to repeal the funding mechanism for the transitional reinsurance program in the individual market, and for other purposes.
H.R. 2712 - To streamline the employer reporting process and strengthen the eligibility verification process for the health care premium tax credit and cost-sharing subsidy, and for other purposes.
H.R. 2017 - To amend the Federal Food, Drug, and Cosmetic Act to improve and clarify certain disclosure requirements for restaurants and similar retail food establishments, and to amend the authority to bring proceedings under section 403A.
H.R. 928/S. 183 - To repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act.
H.R. 3020 - Departments of Labor, Health and Human Services, and Education and Related Agencies Appropriations Act, 2016
H.R. 3112 - BE OPEN Act
S. 1996 - Commonsense Reporting Act of 2015
S. 2045 - Middle Class Health Benefits Tax Repeal Act of 2015
S. 2075 - American Worker Health Care Tax Relief Act of 2015
House Education and Workforce Committee Reconciliation Recommendations pursuant to S. Con. Res. 11, the Concurrent Resolution on the Budget for Fiscal Year 2016
House Ways and Means Committee Reconciliation Recommendations pursuant to S. Con. Res. 11, the Concurrent Resolution on the Budget for Fiscal Year 2016
H.R. 592 / S. 314 - Pharmacy and Medically Underserved Areas Enhancement Act
H.R. 2029 - Consolidated Appropriations Act, House Amendments 1 and 2 to Senate Amendment published as Rules Committee Prints 114-39 and 114-40
H.R. 1314 - Bipartisan Budget Act of 2015
H.R.3762 - Restoring Americans' Healthcare Freedom Reconciliation Act of 2015
S.1946 - Tax Relief Extension Act of 2015
S.2045 - Middle Class Health Benefits Tax Repeal Act of 2015
Client expense: $150,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
H.R.3250/S. 2994 - DXM Abuse Prevention Act of 2015
H.R. 1270 / S. 620 - Restore Access to Medication Act
H.R. 592 / S. 314 - Pharmacy and Medically Underserved Areas Enhancement Act
H.R. 2029 - Consolidated Appropriations Act, House Amendments 1 and 2 to Senate Amendment published as Rules Committee Prints 114-39 and 114-40
H.R.3762 - Restoring Americans' Healthcare Freedom Reconciliation Act of 2015
H.R. 793/S. 1190 - the Ensuring Seniors Access to Local Pharmacies Act
Health Savings Act of 2016 - H.R.4469/S.2499
H.R. 5951/S. 3308 - Improving Transparency and Accuracy in Medicare Part D Spending Act
Client expense: $150,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
Client expense: $310,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
HR 6, 21st Century Cures Act; HR 592/S 314, Pharmacy and Medically Underserved Areas Enhancement Act; S 524, Comprehensive Addiction and Recovery Act of 2016; provisions related to pharmacy and consultant pharmacy
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE